Tomorrow
Helping create a healthier future for Canadians
Among the challenges that define the future of Canada’s health systems, one of the most critical will be ensuring plasma sufficiency. This is a core responsibility of Canadian Blood Services and a pillar of our strategic plan. As the medical applications of immune globulin (Ig) continue to grow, we’re seeing a steady rise in the volume of plasma needed to manufacture Ig drugs. In taking concrete steps to safeguard Canada’s plasma supply, we’re working with prescribers, patient groups and health ministries on a coordinated response to this global challenge.
Cayleigh Kearns
Plasma protein product recipient
